(19)
(11) EP 4 770 677 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 23950868.2

(22) Date of filing: 28.08.2023
(51) International Patent Classification (IPC): 
A61K 47/68(2017.01)
A61P 11/06(2006.01)
A61P 9/10(2006.01)
A61P 35/00(2006.01)
A61K 47/65(2017.01)
A61P 31/06(2006.01)
A61P 9/12(2006.01)
C07K 16/28(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 9/12; A61P 9/10; A61P 11/06; A61P 31/06; A61P 35/00; C07K 16/28; A61K 47/6843; A61K 47/6889; A61K 47/68031; A61K 47/68037; A61K 47/6851; C07K 16/18; A61K 2039/505
(86) International application number:
PCT/KR2023/012720
(87) International publication number:
WO 2025/047993 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(71) Applicant: Pharosgen Co., Ltd.
Seoul 05852 (KR)

(72) Inventors:
  • BYUN, Youngro
    Seoul 01318 (KR)
  • LEE, Ha Kyeong
    Seoul 05504 (KR)
  • CHUNG, Seungwoo
    Yongin-si Gyeonggi-do 16908 (KR)
  • KIM, Byoung Mo
    Seoul 08793 (KR)
  • CHOI, So-Young
    Sejong 30130 (KR)
  • LEE, Se-Ra
    Sejong 30124 (KR)

(74) Representative: Zaccaro, Elisabetta et al
Notarbartolo & Gervasi S.p.A. Viale Achille Papa, 30
20149 Milano
20149 Milano (IT)

   


(54) ANTI-DOPPEL ANTIBODY DRUG CONJUGATES